BioCentury | Apr 15, 2013
Company News

Igen, Boehringer Mannheim GmbH deal

IGEN received a $6 million advance payment on 1997 royalties from partner Boehringer Mannheim. The payments arise from sales of the pharma company's Elecsys series of immunodiagnostics based on IGEN's Origen technology. Origen provides uniform...
BioCentury | Apr 15, 2013
Company News

Igene management update

Igene Biotechnology Inc. (IGNE), Columbia, Md. Business: Agbio/Veterinary/Environmental Hired: Ramin Abrishamian,as CEO; formerly a consultant in technology and product commercialization WIR Staff...
BioCentury | May 7, 2012
Company News

Neogen, Sanofi deal

Neogen said it acquired the Igenity animal genomics business from Sanofi's Merial Ltd. animal health division. Igenity will relocate operations to Lincoln, Neb., to operate as part of Neogen's GeneSeek animal genomics subsidiary, which serves...
BioCentury | Apr 9, 2007
Company News

BioVeris, Roche deal

ROG said it will acquire BIOV for $21.50 per share in cash, or about $600 million. The deal price is a 58% premium to BIOV's close of $13.60 on April 3, the day before the...
BioCentury | Nov 21, 2005
Company News

Orchid Cellmark, Merck, sanofi-aventis deal

ORCH received a two-year contract to provide cattle genotyping services to Merial, a joint venture between SAN and MRK. The deal will support Merial's Igenity service, which provides breeders with genetic data relating to characteristics...
BioCentury | Jun 20, 2005
Strategy

PharM&A

PharM&A Year Buyer Target Description 2005 Bayer Roche Consumer Health Bought Roche's OTC business for CHF3.6B ($2.8B) 2005 Daiichi Sankyo (A) Daiichi and Sankyo merged to form Daiichi Sankyo, which will focus on cardiovascular, anti-bacterial,...
BioCentury | Jun 7, 2004
Company News

BioVeris sales and marketing update

BIOV (formerly Igen International Inc. ) launched its M-Series M1M automated analyzer for use with its BioVerify kits to detect biological warfare agents. BioVeris Corp. (BIOV), Gaithersburg, Md. Business: Diagnostic WIR Staff Diagnostic...
BioCentury | Feb 23, 2004
Company News

BioVeris Inc., Igen, Roche deal

ROCZ completed its acquisition of Igen for $1.3 billion in cash and stock (see BioCentury, July 28, 2003). ROCZ renamed the unit BioVeris. IGEN shareholders will receive $47.25 in cash and one BIOV share for...
BioCentury | Jul 28, 2003
Finance

Ebb & Flow

Wall Street expects companies to provide guidance on revenues. But if it's hard to forecast product sales precisely, it's even more difficult to predict partnership deal flow. Toolkit companies found out the hard way by...
BioCentury | Jul 28, 2003
Company News

Igen, Roche deal

ROCZ will acquire IGEN for $1.3 billion in cash plus stock in a newly formed spinoff. As a result of the deal, ROCZ has secured rights to IGEN's Origen electrochemiluminescence technology used in its Elecsys...
Items per page:
1 - 10 of 146
BioCentury | Apr 15, 2013
Company News

Igen, Boehringer Mannheim GmbH deal

IGEN received a $6 million advance payment on 1997 royalties from partner Boehringer Mannheim. The payments arise from sales of the pharma company's Elecsys series of immunodiagnostics based on IGEN's Origen technology. Origen provides uniform...
BioCentury | Apr 15, 2013
Company News

Igene management update

Igene Biotechnology Inc. (IGNE), Columbia, Md. Business: Agbio/Veterinary/Environmental Hired: Ramin Abrishamian,as CEO; formerly a consultant in technology and product commercialization WIR Staff...
BioCentury | May 7, 2012
Company News

Neogen, Sanofi deal

Neogen said it acquired the Igenity animal genomics business from Sanofi's Merial Ltd. animal health division. Igenity will relocate operations to Lincoln, Neb., to operate as part of Neogen's GeneSeek animal genomics subsidiary, which serves...
BioCentury | Apr 9, 2007
Company News

BioVeris, Roche deal

ROG said it will acquire BIOV for $21.50 per share in cash, or about $600 million. The deal price is a 58% premium to BIOV's close of $13.60 on April 3, the day before the...
BioCentury | Nov 21, 2005
Company News

Orchid Cellmark, Merck, sanofi-aventis deal

ORCH received a two-year contract to provide cattle genotyping services to Merial, a joint venture between SAN and MRK. The deal will support Merial's Igenity service, which provides breeders with genetic data relating to characteristics...
BioCentury | Jun 20, 2005
Strategy

PharM&A

PharM&A Year Buyer Target Description 2005 Bayer Roche Consumer Health Bought Roche's OTC business for CHF3.6B ($2.8B) 2005 Daiichi Sankyo (A) Daiichi and Sankyo merged to form Daiichi Sankyo, which will focus on cardiovascular, anti-bacterial,...
BioCentury | Jun 7, 2004
Company News

BioVeris sales and marketing update

BIOV (formerly Igen International Inc. ) launched its M-Series M1M automated analyzer for use with its BioVerify kits to detect biological warfare agents. BioVeris Corp. (BIOV), Gaithersburg, Md. Business: Diagnostic WIR Staff Diagnostic...
BioCentury | Feb 23, 2004
Company News

BioVeris Inc., Igen, Roche deal

ROCZ completed its acquisition of Igen for $1.3 billion in cash and stock (see BioCentury, July 28, 2003). ROCZ renamed the unit BioVeris. IGEN shareholders will receive $47.25 in cash and one BIOV share for...
BioCentury | Jul 28, 2003
Finance

Ebb & Flow

Wall Street expects companies to provide guidance on revenues. But if it's hard to forecast product sales precisely, it's even more difficult to predict partnership deal flow. Toolkit companies found out the hard way by...
BioCentury | Jul 28, 2003
Company News

Igen, Roche deal

ROCZ will acquire IGEN for $1.3 billion in cash plus stock in a newly formed spinoff. As a result of the deal, ROCZ has secured rights to IGEN's Origen electrochemiluminescence technology used in its Elecsys...
Items per page:
1 - 10 of 146